查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1857410

抗寄生蟲藥物市場（按藥物類別和獸用分類）－2025年至2032年全球預測

Antiparasitic Drugs Market by Drug Class, Veterinary - Global Forecast 2025-2032
出版日期: | 出版商: 360iResearch | 英文 190 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2032 年，抗寄生蟲藥物市場規模將達到 309.8 億美元，複合年成長率為 4.90%。

關鍵市場統計數據
基準年 2024 211.2億美元
預計年份：2025年 221.8億美元
預測年份 2032 309.8億美元
複合年成長率 (%) 4.90%

在臨床和獸醫領域全面推廣抗寄生蟲治療，突顯創新和管理的策略重點。

抗寄生蟲治療領域涵蓋廣泛且不斷發展，包括科學創新、不斷變化的監管環境以及獸醫和臨床護理中終端用戶需求的轉變。本導言透過描述主要藥物類別、治療用途以及影響產品開發和分銷的商業性因素，確立了分析的範圍。此外，本導言也將抗寄生蟲藥物置於一個相互關聯的生態系統中，其中抗藥性管理、製劑適應性和供應鏈韌性決定了其長期生存能力和臨床相關性。

參與藥物研發、生產和商業化的相關人員必須了解差異化治療方法如何從分子創新中湧現，以及能夠提升安全性、給藥便利性和物種特異性療效的製劑技術。此外，法律規範和藥物管理計畫對適應症擴展、仿單標示外用藥考量和核准後義務的影響日益顯著。因此，本導言旨在為報告的更廣泛目標奠定基礎：在科學、政策和市場快速變化的環境下，為循證優先排序、營運協調和跨職能決策提供策略基礎。

有了這個通用的基準，接下來的章節將基於機制考慮和行業動態，確定哪些投資和合作能夠帶來最大價值，同時管理與韌性趨勢和貿易相關中斷有關的下行風險。

抗寄生蟲藥物研發和供應的策略轉型：由分子創新、監管協調和基於診斷的管理所驅動

由於分子化學的進步、綜合蟲害管理理念的推廣以及監管機構對抗藥性防治日益重視，抗寄生蟲藥物領域正經歷顯著的變化。新型化合物類別和標靶製劑能夠延長藥效並提高安全性，而數位化工具的出現則進一步促進了診斷、監測和終端用戶的用藥依從性。因此，該行業正朝著精準抗寄生蟲策略轉型，優先考慮宿主特異性給藥、環境管理和最大限度減少附帶暴露。

同時，由於分銷模式的改變以及對生技藥品和聯合治療的日益重視，競爭格局正在改變。為了維持標籤價值並證明其高階定位的合理性，製造商正擴大整合生命週期管理策略，並納入真實世界證據。同時，監管機構和產業之間也加強了合作，共同製定替代給藥方案和新適應症的途徑，從而縮短從創新到臨床或獸醫應用的時間。因此，能夠將科學差異化、適應性監管策略和強大的市場推廣能力相結合的公司，將最有優勢引領下一波治療藥物的推廣應用浪潮。

最後，這些因素的匯合促使相關人員重新思考傳統的產品系列，優先考慮診斷相關治療方法等綜合提案主張，並投資於管理通訊協定，以維持治療效用，同時滿足獸醫、生產者和飼主不斷變化的期望。

對2025年美國關稅將如何改變全球抗寄生蟲藥物產業的供應鏈設計、籌資策略和商業性定位進行全面評估

2025年美國關稅的累積影響將為抗寄生蟲藥物供應鏈和商業策略帶來複雜的貿易風險和營運調整。關稅調整不僅會影響直接成本，還會影響採購決策、合約製造外包關係以及國內生產與海外生產的相對吸引力。因此，採購團隊和業務規劃人員正在重新評估供應商多元化和近岸外包方案，以降低關稅波動帶來的風險，並確保原料藥和成品藥的持續供應。

此外，關稅波動會與外匯波動、運費波動和監管合規要求相互作用，加劇對到岸成本和庫存策略的影響。因此，擁有全球企業發展的公司必須權衡集中式生產的規模優勢和區域生產基地的彈性，後者能更好地吸收政策衝擊。在實踐中，這意味著要優先考慮策略採購、庫存緩衝和雙重採購安排，以確保關鍵零件的供應，同時在終端市場實現價格競爭。

除了生產製造和採購之外，關稅也會影響商業策略。定價委員會、報銷規劃人員和合約負責人正在重新審視關於供應商長期承諾和經銷夥伴的假設。他們也正在建構各種方案模型，包括付費生產合作關係以及在法規、勞動力和資本允許的情況下對國內產能進行策略性投資。總而言之，這些調整反映了現實世界的變化。企業正在將貿易政策情境納入其企業風險管理，以確保在更廣泛的外部環境下維持治療方案的可及性和利潤目標。

透過對藥物類別和動物用藥品子類別中機制差異進行深入的細分分析，從而指導藥物開發、管理和商業化選擇。

透過細緻的細分視角，我們可以揭示治療藥物類別和獸用應用如何影響研發重點和市場行為。藥物類別包括氨基乙腈類（如莫能泮）、苯並咪唑類（如阿苯達唑、芬苯達唑、甲苯達唑、奧昔苯達唑和噻苯達唑）、苯並咪唑酮（如阿維菌素、多拉菌素、依普利菌素和伊維菌素）以及螺吲哚類（如德康特素）。每類藥物的作用機制和安全性與有效性之間的權衡各不相同，從而決定了其首選應用場景。藥物動力學和抗藥性特徵的差異使得某些類別的藥物更適合特定的宿主物種和流行病學情況，進而影響製劑選擇和管理通訊協定。

結合獸醫細分市場，可以進一步精進戰略意義。在水產養殖中，魚蝦是獨立的生物和生產系統，因此治療給藥方式和環境影響等因素決定了活性成分的選擇和給藥方案。對於犬貓等伴侶動物，耐受性、給藥便利性和飼主便利性是首要考慮因素，因此口服咀嚼片、局部製劑和長效注射劑等符合動物依從性的製劑更受青睞。在畜牧生產中，以牛、家禽和豬為目標，飼料和飲水相容性、停藥期和養殖規模等因素會影響決策，生產者傾向於選擇穩健、經濟高效且能最大限度減少生產中斷的解決方案。

因此，兼顧藥物類別特性和獸藥領域需求的綜合產品策略優於一刀切的方法。研發藍圖應包含物種特異性安全性研究、針對特定生產系統特有的抗藥性風險的管理計劃，以及根據獸醫和生產商的採購和管理實踐量身定做的商業化策略。

亞太地區、歐洲以及中東和非洲的戰略要務影響抗寄生蟲產品的監管、分銷和商業化優先事項。

擁有有效策略的公司對監管預期、分銷網路和終端用戶偏好具有強大的影響力，因此需要在關鍵區域採取差異化策略。在美洲，市場促進因素包括成熟的獸醫服務環境、較高的伴侶動物留存率以及優先考慮生產力和生物安全的先進畜牧生產系統。這些條件有利於創新配方和綜合服務的推廣，也為試點計畫奠定了基礎，這些試點計畫能夠在商業性實際條件下驗證產品的功效和管理效果。

相反，歐洲、中東和非洲（EMEA）的管理體制和生產模式呈現出複雜多樣的特點，有些地區監管標準嚴格，而有些地區則資源匱乏。因此，企業必須將全球統一的品質系統與在地化的註冊策略相協調，並做好準備支援能力建構工作，以加強診斷能力，促進在不同環境下負責任地使用產品。此外，在該地區的部分地區，環境法規和社會監督提高了人們對殘留物管理和生態系統影響的期望，這對產品設計和上市後監測都產生了影響。

亞太地區生產系統快速現代化，生物多樣性豐富，監管環境複雜多樣，因此既注重可擴展的生產，也重視可靠的安全性資料。該地區往往引領著具成本效益學名藥和替代劑型的普及，同時又為都市區伴侶動物市場的高級產品提供了機會。鑑於這些區域性特點，需要靈活的商業化模式，平衡區域夥伴關係、監管靈活性和有針對性的證據生成，以支持產品的持續推廣應用。

企業動態和夥伴關係模式能夠加速抗寄生蟲藥物創新，同時兼顧生命週期管理、供應彈性和監管義務。

活躍於抗寄生蟲治療領域的主要企業正在整合科學平台、拓展服務提案，並打破傳統產品界限以夥伴關係。產業巨頭正加大對製劑科學的投入，以提高產品的易用性和依從性，同時利用現場數據來展示療效對比和管理成果。製藥廠商、診斷公司和分銷網路之間的策略聯盟正在促成產品組合的推出，從而增強處方信心並鞏固長期客戶關係。

同時，擁有專注產品組合的中型創新企業正透過加速新型化合物的研發進度或拓展適應症以滿足特定物種或生產系統中的未滿足需求，從而掌握利基市場機會。這些公司通常利用策略授權合約和共同開發契約來擴大生產規模並更有效地拓展分銷管道。此外，合約開發和受託製造公司也發揮關鍵作用，它們提供靈活的產能以支持快速進入市場，並促進供應鏈的地理多元化，從而應對貿易政策風險。

這種多元化的競爭格局凸顯了跨職能協作的重要性，研發、監管和商業團隊需要攜手合作，以最佳化產品生命週期價值。那些將卓越技術與敏捷的夥伴關係模式結合的公司，最能掌握創新帶來的長期效益，同時保持良好的產品管理和持續的供應保障。

為領導者提供行動建議，以協調創新、管理和貿易意識強的供應鏈策略，從而保護治療價值和商業性韌性

產業領導者應優先考慮一系列切實可行的舉措，使科學創新與現實的商業性需求和監管環境相契合。首先，投資差異化製劑和伴隨診斷將提升治療價值，並支持實證應用。這種方法將透過降低仿單標示外風險和實現標靶治療來加強監管。其次，將貿易政策情境規劃納入採購和生產策略將增強供應鏈韌性，使企業能夠在不影響臨床或獸醫服務連續性的前提下，主動應對關稅變化和運輸中斷。

第三，企業應將管理計畫正式化，包括實地教育、抗藥性監測以及與監管機構和從業人員透明的數據共用，從而維持長期有效性並維護品牌聲譽。第四，在診斷、分銷和契約製造建立策略夥伴關係，特別是結合以結果為導向、協調價值鏈各環節獎勵的商業模式，可以加速市場進入並降低產能擴張的風險。最後，使商業性訊息與當地監管預期和終端用戶行為相符，可以最大限度地提高市場准入率。這需要投資於針對特定市場的證據產生和量身定做的參與策略，以反映特定物種的監管實踐和生產者的經濟狀況。

綜合來看，這些行動構成了一個切實可行的藍圖，可以將科學進步轉化為永續的、盈利的干涉措施，從而在全球市場保持治療效用並滿足相關人員的期望。

我們採用透明的調查方法，結合專家訪談、監管機構審查和情境驅動分析，以確保提供可重複且可用於決策的情報。

本研究整合了一手和二手研究，建構了一個嚴謹、透明且可重複的分析基礎。一手資料包括對藥物發現、藥品事務、獸醫實踐和商業性營運等領域的專家進行的結構化訪談，並輔以對同行評審文獻和監管指導文件的技術性審查。二手研究則包括對公開文件、安全建議和已發布的抗藥性監測報告進行評估性審查，以驗證訊號並檢驗專家意見。

此分析方法結合了定性主題分析和基於情境的風險評估，旨在突顯策略脆弱性和機會領域。透過比較案例研究，闡明了不同的管理體制和生產系統如何影響生命週期策略；並利用供應鏈圖譜可視化了採購依賴關係和關稅風險點。研究過程中，始終記錄了調查方法的假設、資料來源和局限性，以確保結論具有情境性，並能應用於決策者的營運規劃和投資組合優先順序。

最後，我們與外部專家和內部相關人員進行了多次迭代檢驗會議，以完善我們的解釋，並確保最終分析能夠反映技術準確性和對研發、製造和商業領域使用者的實際相關性。

最終的綜合分析強調，需要製定整合策略，在維持治療效用的同時，平衡創新、管理和貿易韌性。

總之，抗寄生蟲藥物領域正處於曲折點，分子創新、不斷變化的監管預期以及貿易政策壓力正在重新定義研發者、製造商和經銷商的戰略重點。最成功的企業將是那些將差異化的科學方法與對管理、靈活的籌資策略以及反映物種特定政府和區域監管細微差別的本地化商業化計劃相結合的企業。透過這樣做，它們可以在伴侶動物、水產養殖和畜牧業領域開闢永續成長的新途徑，同時保持治療效果。

展望未來，持續投資於診斷、積極參與監管以及進行協作式管理對於維持長期治療價值至關重要。那些果斷採取行動，使其內部能力與外部現實（例如關稅執法、抗藥性監測和終端用戶行為等）相適應的公司，將更有能力克服不確定性，並抓住不斷變化的全球動態帶來的機會。這項結論強調了製定整合策略規劃的必要性，該規劃應將洞察轉化為貫穿產品生命週期和價值鏈的可衡量行動。

目錄

第1章：序言

第2章調查方法

第3章執行摘要

第4章 市場概覽

第5章 市場洞察

  • 在開發中地區擴大以伊維菌素為基礎的聯合治療在抗藥性蠕蟲病治療的應用
  • 創新局部製劑可提高抗寄生蟲藥物的經皮滲透性，用於治療疥瘡
  • 擴大獸用抗寄生蟲生技藥品的使用範圍，以預防牲畜寄生蟲感染，進而減少農藥殘留。
  • 非洲大規模藥物管理計劃中對單劑量口服大環內酯類藥物的需求日益成長
  • 新興的奈米藥物遞送系統可提高抗寄生蟲藥物的療效和患者依從性。
  • 增加數位診斷平台的投資，以便快速檢測偏遠地區的寄生蟲感染

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

8. 依藥物類別分類的抗寄生蟲藥物市場

  • 氨基乙腈
    • 莫奈潘特
  • 苯並咪唑酮
    • 阿苯達唑
    • 芬苯達唑
    • 甲苯咪唑
    • 奧昔苯達唑
    • THIABENDAZOLE
  • 大環內酯
    • Avermectin
    • 多拉菌素
    • 依普利諾菌素
    • 伊維菌素
  • 螺吲哚
    • 德爾昆特爾

9. 獸用抗寄生蟲藥物市場

  • 水產養殖
    • 魚
    • 蝦
  • 伴侶動物
    • 狗
    • 貓
  • 家畜
    • 牛
    • 家禽
    • 豬

第10章 各地區抗寄生蟲藥物市場

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第11章 抗寄生蟲藥物市場（按類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第12章：各國抗寄生蟲藥物市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第13章 競爭格局

  • 2024年市佔率分析
  • FPNV定位矩陣，2024
  • 競爭分析
    • Zoetis Inc.
    • Merck & Co., Inc.
    • Boehringer Ingelheim International GmbH
    • Elanco Animal Health Incorporated
    • Bayer AG
    • Ceva Sante Animale SA
    • Virbac SA
    • Dechra Pharmaceuticals PLC
    • Vetoquinol SA
    • Norbrook Laboratories Limited
Product Code: MRR-B16853777759

The Antiparasitic Drugs Market is projected to grow by USD 30.98 billion at a CAGR of 4.90% by 2032.

KEY MARKET STATISTICS
Base Year [2024] USD 21.12 billion
Estimated Year [2025] USD 22.18 billion
Forecast Year [2032] USD 30.98 billion
CAGR (%) 4.90%

Comprehensive introduction framing antiparasitic therapeutics across clinical and veterinary domains while highlighting strategic priorities for innovation and stewardship

The landscape of antiparasitic therapeutics encompasses a broad and evolving combination of scientific innovation, regulatory change, and shifting end-user needs across veterinary and clinical care. This introduction establishes the scope of analysis by contextualizing core drug classes, therapeutic applications, and the commercial imperatives that shape product development and distribution. It situates antiparasitic agents within an interconnected ecosystem where resistance management, formulation adaptability, and supply chain resilience determine long-term viability and clinical relevance.

Stakeholders operating in discovery, manufacturing, and commercialization should understand how therapeutic differentiation emerges from molecular innovation as well as from formulation technologies that improve safety, dosing convenience, and species-specific efficacy. In addition, regulatory frameworks and stewardship programs increasingly influence label expansions, off-label use considerations, and post-approval obligations. Consequently, this introduction frames the report's broader objective: to provide a strategic foundation that supports evidence-based prioritization, operational alignment, and cross-functional decision-making in an environment of accelerating scientific, policy, and market change.

By establishing this common baseline, the subsequent sections build on mechanistic considerations and sectoral dynamics to reveal where investments and collaborations will deliver the highest value while managing downside risks associated with resistance trends and trade-related disruptions.

Strategic transformation in antiparasitic development and delivery driven by molecular innovation, regulatory alignment, and diagnostic-enabled stewardship

The antiparasitic landscape is undergoing transformative shifts driven by advances in molecular chemistry, integrated pest management philosophies, and a heightened regulatory focus on resistance mitigation. New compound classes and targeted formulations are enabling longer durations of efficacy and improved safety profiles, and this scientific progress is being complemented by digital tools that improve diagnosis, monitoring, and adherence across end users. Consequently, the industry is moving toward precision antiparasitic strategies that prioritize host-specific dosing, environmental stewardship, and minimized collateral exposure.

At the same time, changes in distribution models and an expanding emphasis on biologics and combination therapies are altering competitive dynamics. Manufacturers are increasingly integrating lifecycle management strategies that incorporate real-world evidence to sustain label value and justify premium positioning. This shift is occurring in parallel with more proactive collaboration between regulators and industry to define pathways for alternative dosing regimens and novel indications, thereby shortening the time from innovation to clinical or veterinary adoption. As a result, companies that can combine scientific differentiation with adaptive regulatory strategies and strong field-level engagement will be best positioned to lead the next wave of therapeutic uptake.

Finally, the confluence of these factors encourages stakeholders to rethink traditional product portfolios, prioritize integrated value propositions such as diagnostic-linked therapies, and invest in stewardship protocols that preserve therapeutic utility while meeting evolving expectations from veterinarians, producers, and pet owners.

Comprehensive evaluation of how United States tariff measures in 2025 reshape supply chain design, procurement strategy, and commercial positioning across global antiparasitic operations

The cumulative impact of United States tariff actions in 2025 introduces a complex layer of trade-related risk and operational recalibration for antiparasitic supply chains and commercial strategies. Tariff adjustments have ripple effects beyond direct cost implications: they influence sourcing decisions, contract manufacturing relationships, and the relative attractiveness of domestic versus international production. In turn, procurement teams and business planners are reassessing supplier diversification and nearshoring options to mitigate exposure to tariff volatility and to maintain continuity of supply for both active pharmaceutical ingredients and finished formulations.

Moreover, tariff dynamics interact with currency movements, freight cost variability, and regulatory compliance requirements, producing compound effects on landed costs and inventory policies. Companies with global footprints must therefore balance the benefits of centralized manufacturing scale against the flexibility of regional production nodes that can absorb policy shocks more readily. In practice, this means that strategic procurement, inventory buffering, and dual-sourcing agreements are being prioritized to preserve access to critical components while enabling price competitiveness in end markets.

Beyond manufacturing and procurement, tariffs also affect commercial strategy. Pricing committees, reimbursement planners, and contract negotiators are revisiting assumptions about long-term supplier commitments and distribution partnerships. They are also modeling pathway options that include toll-manufacturing relationships and strategic investments in domestic capacity where regulatory, labor, and capital considerations permit. Taken together, these adjustments reflect a pragmatic shift: organizations are embedding trade-policy scenarios into enterprise risk management to ensure that therapeutic availability and margin objectives are maintained under a wider range of external conditions.

Insightful segmentation analysis that interrelates drug-class mechanistic differences with veterinary subcategories to drive development, stewardship, and commercialization choices

A nuanced segmentation lens clarifies how therapeutic class and veterinary application jointly shape development priorities and market behavior. Drug class segmentation spans Amino-Acetonitrile chemistries such as Monepantel, Benzimidazoles including Albendazole, Fenbendazole, Mebendazole, Oxibendazole, and Thiabendazole, Macrocyclic Lactones represented by Abamectin, Doramectin, Eprinomectin, and Ivermectin, as well as Spiroindoles exemplified by Derquantel, each bringing distinct mechanisms of action and safety-efficacy trade-offs that determine preferred use cases. Differences in pharmacokinetics and resistance profiles make certain classes more suitable for particular host species and epidemiological contexts, thereby influencing formulation choices and stewardship protocols.

Overlaying this with veterinary segmentation further refines strategic implications. In aquaculture, where fish and shrimp represent separate biological and production systems, treatment delivery methods and environmental impact considerations dictate the selection of active ingredients and dosing regimens. Companion animal contexts such as canine and feline care prioritize tolerability, ease of administration, and owner convenience, which favors oral chewables, topical formulations, and long-acting injectables that align with adherence behaviors. In livestock contexts covering cattle, poultry, and swine, decision drivers include feed and water compatibility, withdrawal periods, and operational scale, with producers favoring robust, cost-efficient solutions that minimize production disruption.

Consequently, integrated product strategies that consider both drug-class attributes and veterinary segment needs will outperform one-size-fits-all approaches. Development roadmaps should incorporate species-specific safety studies, stewardship plans that address resistance risks endemic to particular production systems, and commercialization tactics tailored to the procurement and administration practices of veterinarians and producers.

Regional strategic imperatives across Americas, Europe Middle East & Africa, and Asia-Pacific that shape regulatory, distribution, and commercialization priorities for antiparasitic products

Regional dynamics exert strong influence on regulatory expectations, distribution networks, and end-user preferences, requiring differentiated strategies across major geographies. In the Americas, market drivers are shaped by a mature veterinary services environment, high companion animal ownership rates, and advanced livestock production systems that prioritize productivity and biosecurity. These conditions favor innovative formulations and integrated service offerings, and they also create a platform for pilot programs that demonstrate efficacy and stewardship outcomes under commercially realistic conditions.

Conversely, Europe, Middle East & Africa present a mosaic of regulatory regimes and production modalities, with stringent regulatory standards in some jurisdictions and resource-constrained environments in others. Consequently, companies must reconcile uniform global quality systems with locally adapted registration strategies, and they must be prepared to support capacity-building efforts that enhance diagnostic capability and responsible use in diverse settings. In addition, environmental regulations and public scrutiny in parts of this region heighten expectations around residue control and ecological impact, influencing both product design and post-market surveillance.

The Asia-Pacific region combines rapidly modernizing production systems with high biodiversity and varied regulatory landscapes, prompting a dual focus on scalable manufacturing and robust safety data. This region often leads in adoption of cost-effective generics and alternative delivery formats, while simultaneously presenting opportunities for differentiated, premium products in urban companion-animal markets. Together, these regional contingencies necessitate flexible commercialization models that balance local partnerships, regulatory agility, and targeted evidence generation to support sustained uptake.

Corporate dynamics and partnership models that accelerate antiparasitic innovation while balancing lifecycle management, supply resilience, and stewardship obligations

Leading companies active in antiparasitic therapeutics are consolidating scientific platforms, expanding service propositions, and forming partnerships that extend beyond traditional product boundaries. Industry incumbents are investing in formulation science to enhance ease of use and compliance, while simultaneously leveraging field-level data to demonstrate comparative performance and stewardship outcomes. Strategic alliances between pharmaceutical manufacturers, diagnostic firms, and distribution networks are enabling bundled offerings that improve prescribing confidence and strengthen long-term customer relationships.

At the same time, mid-sized innovators with focused portfolios are capitalizing on niche opportunities by accelerating development timelines for new chemical entities and by pursuing label expansions that address unmet needs in specific species or production systems. These companies often rely on strategic licensing and co-development agreements to scale manufacturing and access distribution channels more efficiently. Meanwhile, contract development and manufacturing organizations are playing a critical role by providing flexible capacity that supports rapid market entry and by enabling geographic diversification of supply chains to manage trade-policy exposure.

Collectively, this competitive landscape emphasizes the importance of cross-functional collaboration, where R&D, regulatory affairs, and commercial teams coordinate to optimize lifecycle value. Companies that combine technical excellence with agile partnership models will be best positioned to capture the long-term benefits of innovation while maintaining robust stewardship and supply continuity.

Actionable recommendations for leaders to align innovation, stewardship, and trade-aware supply chain strategies to protect therapeutic value and commercial resilience

Industry leaders should prioritize a set of actionable initiatives that align scientific innovation with practical commercial imperatives and regulatory realities. First, investing in differentiated formulations and companion diagnostics will increase therapeutic value and support evidence-based adoption; this approach reduces off-label risks and strengthens stewardship by enabling targeted treatment. Second, embedding trade-policy scenario planning into procurement and manufacturing strategies will enhance supply chain resilience, allowing organizations to respond proactively to tariff shifts and transport disruptions without disrupting clinical and veterinary continuity.

Third, companies should formalize stewardship programs that include field-level education, resistance monitoring, and transparent data sharing with regulators and practitioners, thereby preserving long-term efficacy and protecting brand reputation. Fourth, strategic partnerships across diagnostics, distribution, and contract manufacturing can accelerate market access and de-risk capacity expansion, particularly when combined with outcome-driven commercial models that align incentives across the value chain. Finally, aligning commercial messaging with local regulatory expectations and end-user behaviors will maximize uptake; this requires investment in market-specific evidence generation and tailored engagement strategies that reflect species-specific administration practices and producer economics.

Taken together, these actions form a practical roadmap for translating scientific advances into sustainable, profitable interventions that maintain therapeutic utility and meet stakeholder expectations across global markets.

Transparent research methodology combining expert interviews, regulatory review, and scenario-driven analysis to ensure reproducible and decision-ready intelligence

This research synthesizes primary and secondary evidence to produce a rigorous, transparent, and reproducible analytical foundation. Primary inputs included structured interviews with subject-matter experts across discovery, regulatory affairs, veterinary practice, and commercial operations, complemented by technical reviews of peer-reviewed literature and regulatory guidance documents. Secondary research encompassed an evaluative review of public filings, safety advisories, and published resistance surveillance reports to triangulate signals and validate expert perspectives.

Analytical methods combined qualitative thematic analysis with scenario-based risk assessment to surface strategic vulnerabilities and opportunity areas. Comparative case studies were used to illustrate how different regulatory regimes and production systems shape lifecycle strategies, while supply chain mapping provided visibility into sourcing dependencies and tariff exposure points. Throughout, care was taken to document assumptions, data provenance, and methodological limitations, ensuring that conclusions are contextualized and actionable for decision-makers seeking to apply the findings to operational planning and portfolio prioritization.

Finally, iterative validation sessions with external experts and internal stakeholders were conducted to refine interpretations and ensure that the final analysis reflects both technical accuracy and practical relevance for users across R&D, manufacturing, and commercial functions.

Final synthesis highlighting the imperative for integrated strategies that preserve therapeutic utility while aligning innovation, stewardship, and trade resilience

In conclusion, the antiparasitic domain is at an inflection point where molecular innovation, shifting regulatory expectations, and trade-policy pressures converge to redefine strategic priorities for developers, manufacturers, and distributors. The most successful organizations will be those that integrate differentiated scientific approaches with stewardship commitments, resilient sourcing strategies, and localized commercialization plans that reflect species-specific administration and regional regulatory nuances. By doing so, they will preserve therapeutic efficacy while unlocking new avenues for sustainable growth across companion animal, aquaculture, and livestock sectors.

Looking ahead, continued investment in diagnostics, adaptive regulatory engagement, and collaborative stewardship will be essential to maintain long-term therapeutic value. Companies that act decisively to align internal capabilities with external realities-particularly around tariff exposure, resistance surveillance, and end-user behavior-will be better equipped to navigate the uncertainties and capture opportunities presented by evolving global dynamics. This conclusion underscores the imperative for integrated strategic planning that translates insight into measurable actions across the product lifecycle and the value chain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Growing adoption of ivermectin-based combination therapies for resistant helminthiasis in developing regions
  • 5.2. Innovative topical formulations improving dermal penetration of antiparasitic agents for scabies treatment
  • 5.3. Expansion of veterinary antiparasitic biologics targeting livestock parasite prevention to reduce chemical residues
  • 5.4. Rising demand for single-dose oral macrocyclic lactone drugs in mass drug administration programs across Africa
  • 5.5. Emergence of nanoformulation delivery systems enhancing antiparasitic drug efficacy and patient compliance
  • 5.6. Increasing investments in digital diagnostic platforms for rapid detection of parasitic infections in remote areas

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antiparasitic Drugs Market, by Drug Class

  • 8.1. Amino-Acetonitrile
    • 8.1.1. Monepantel
  • 8.2. Benzimidazoles
    • 8.2.1. Albendazole
    • 8.2.2. Fenbendazole
    • 8.2.3. Mebendazole
    • 8.2.4. Oxibendazole
    • 8.2.5. Thiabendazole
  • 8.3. Macrocyclic Lactones
    • 8.3.1. Abamectin
    • 8.3.2. Doramectin
    • 8.3.3. Eprinomectin
    • 8.3.4. Ivermectin
  • 8.4. Spiroindoles
    • 8.4.1. Derquantel

9. Antiparasitic Drugs Market, by Veterinary

  • 9.1. Aquaculture
    • 9.1.1. Fish
    • 9.1.2. Shrimp
  • 9.2. Companion Animals
    • 9.2.1. Canine
    • 9.2.2. Feline
  • 9.3. Livestock
    • 9.3.1. Cattle
    • 9.3.2. Poultry
    • 9.3.3. Swine

10. Antiparasitic Drugs Market, by Region

  • 10.1. Americas
    • 10.1.1. North America
    • 10.1.2. Latin America
  • 10.2. Europe, Middle East & Africa
    • 10.2.1. Europe
    • 10.2.2. Middle East
    • 10.2.3. Africa
  • 10.3. Asia-Pacific

11. Antiparasitic Drugs Market, by Group

  • 11.1. ASEAN
  • 11.2. GCC
  • 11.3. European Union
  • 11.4. BRICS
  • 11.5. G7
  • 11.6. NATO

12. Antiparasitic Drugs Market, by Country

  • 12.1. United States
  • 12.2. Canada
  • 12.3. Mexico
  • 12.4. Brazil
  • 12.5. United Kingdom
  • 12.6. Germany
  • 12.7. France
  • 12.8. Russia
  • 12.9. Italy
  • 12.10. Spain
  • 12.11. China
  • 12.12. India
  • 12.13. Japan
  • 12.14. Australia
  • 12.15. South Korea

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2024
  • 13.2. FPNV Positioning Matrix, 2024
  • 13.3. Competitive Analysis
    • 13.3.1. Zoetis Inc.
    • 13.3.2. Merck & Co., Inc.
    • 13.3.3. Boehringer Ingelheim International GmbH
    • 13.3.4. Elanco Animal Health Incorporated
    • 13.3.5. Bayer AG
    • 13.3.6. Ceva Sante Animale S.A.
    • 13.3.7. Virbac S.A.
    • 13.3.8. Dechra Pharmaceuticals PLC
    • 13.3.9. Vetoquinol S.A.
    • 13.3.10. Norbrook Laboratories Limited

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2032 (%)
  • FIGURE 3. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 4. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2024 VS 2032 (%)
  • FIGURE 5. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY REGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 7. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 8. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 9. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 10. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 11. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 12. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 13. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 14. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 15. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY GROUP, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 16. ASEAN ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 17. GCC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 18. EUROPEAN UNION ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 19. BRICS ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 20. G7 ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 21. NATO ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 22. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2024 VS 2025 VS 2032 (USD MILLION)
  • FIGURE 23. ANTIPARASITIC DRUGS MARKET SHARE, BY KEY PLAYER, 2024
  • FIGURE 24. ANTIPARASITIC DRUGS MARKET, FPNV POSITIONING MATRIX, 2024

LIST OF TABLES

  • TABLE 1. ANTIPARASITIC DRUGS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2024
  • TABLE 3. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, 2018-2024 (USD MILLION)
  • TABLE 4. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, 2025-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 6. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 8. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 10. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 12. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 14. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 16. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 18. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 20. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MONEPANTEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 22. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 24. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 26. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 28. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 30. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 32. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 34. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ALBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 36. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 38. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 40. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FENBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 42. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 44. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 46. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MEBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 48. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 50. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 52. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY OXIBENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 54. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 56. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 58. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY THIABENDAZOLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 60. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 62. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 64. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 65. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 66. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 67. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 68. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 69. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 70. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 71. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 72. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY ABAMECTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 73. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 74. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 75. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 76. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 77. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 78. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DORAMECTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 79. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 80. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 81. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 82. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 83. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 84. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY EPRINOMECTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 85. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 86. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 87. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 88. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 89. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 90. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY IVERMECTIN, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 91. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 92. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 93. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 94. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 95. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 96. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 97. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 98. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 99. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 100. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 101. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 102. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 103. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 104. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY DERQUANTEL, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 105. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 106. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 107. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 108. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 109. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 110. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 111. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 112. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 114. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 115. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 116. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 117. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 118. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 119. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 120. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FISH, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 121. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 122. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 123. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 124. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 125. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 126. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SHRIMP, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 127. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 128. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 129. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 130. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 131. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 132. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 133. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 134. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 135. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 136. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 137. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 138. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 139. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 140. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CANINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 141. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 142. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 143. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 144. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 145. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 146. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY FELINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 147. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 148. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 149. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 150. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 151. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 152. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 153. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 154. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 155. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 156. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 157. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 158. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 159. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 160. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY CATTLE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 161. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 162. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 163. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 164. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 165. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 166. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY POULTRY, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 167. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 168. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 169. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY GROUP, 2018-2024 (USD MILLION)
  • TABLE 170. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY GROUP, 2025-2032 (USD MILLION)
  • TABLE 171. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 172. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY SWINE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 173. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY REGION, 2018-2024 (USD MILLION)
  • TABLE 174. GLOBAL ANTIPARASITIC DRUGS MARKET SIZE, BY REGION, 2025-2032 (USD MILLION)
  • TABLE 175. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 176. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 177. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 178. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 179. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 180. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 181. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 182. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 183. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 184. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 185. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 186. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 187. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 188. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 189. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 190. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 191. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 192. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 193. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 194. AMERICAS ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 195. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 196. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 197. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 198. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 199. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 200. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 201. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 202. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 203. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 204. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 205. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 206. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 207. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 208. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 209. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 210. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 211. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 212. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 213. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 214. NORTH AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 215. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 216. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 217. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 218. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 219. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 220. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 221. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 222. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 223. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 224. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 225. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 226. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 227. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 228. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 229. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 230. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 231. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 232. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 233. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 234. LATIN AMERICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 235. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2018-2024 (USD MILLION)
  • TABLE 236. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SUBREGION, 2025-2032 (USD MILLION)
  • TABLE 237. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 238. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 239. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 240. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 241. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 242. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 243. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 244. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 245. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 246. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 247. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 248. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 249. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 250. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 251. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 252. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 253. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 254. EUROPE, MIDDLE EAST & AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 255. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 256. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 257. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 258. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 259. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 260. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 261. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 262. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 263. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 264. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 265. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 266. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 267. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 268. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 269. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 270. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 271. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 272. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 273. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 274. EUROPE ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 275. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 276. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 277. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 278. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 279. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 280. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 281. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 282. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 283. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 284. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 285. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 286. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 287. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 288. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 289. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 290. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 291. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 292. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 293. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 294. MIDDLE EAST ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 295. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 296. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 297. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 298. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 299. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 300. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 301. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 302. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 303. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 304. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 305. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 306. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 307. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 308. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 309. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 310. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 311. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD MILLION)
  • TABLE 312. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2025-2032 (USD MILLION)
  • TABLE 313. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2018-2024 (USD MILLION)
  • TABLE 314. AFRICA ANTIPARASITIC DRUGS MARKET SIZE, BY LIVESTOCK, 2025-2032 (USD MILLION)
  • TABLE 315. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2018-2024 (USD MILLION)
  • TABLE 316. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COUNTRY, 2025-2032 (USD MILLION)
  • TABLE 317. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2024 (USD MILLION)
  • TABLE 318. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY DRUG CLASS, 2025-2032 (USD MILLION)
  • TABLE 319. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2018-2024 (USD MILLION)
  • TABLE 320. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY AMINO-ACETONITRILE, 2025-2032 (USD MILLION)
  • TABLE 321. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2018-2024 (USD MILLION)
  • TABLE 322. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY BENZIMIDAZOLES, 2025-2032 (USD MILLION)
  • TABLE 323. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2018-2024 (USD MILLION)
  • TABLE 324. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY MACROCYCLIC LACTONES, 2025-2032 (USD MILLION)
  • TABLE 325. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2018-2024 (USD MILLION)
  • TABLE 326. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY SPIROINDOLES, 2025-2032 (USD MILLION)
  • TABLE 327. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2018-2024 (USD MILLION)
  • TABLE 328. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY VETERINARY, 2025-2032 (USD MILLION)
  • TABLE 329. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2018-2024 (USD MILLION)
  • TABLE 330. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY AQUACULTURE, 2025-2032 (USD MILLION)
  • TABLE 331. ASIA-PACIFIC ANTIPARASITIC DRUGS MARKET SIZE, BY COMPANION ANIMALS, 2018-2024 (USD